The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain ...

Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...

The management of Israeli pharma group Teva has laid out its strategy for ... accompanied its takeover in 2017 of generic drugmaker Actavis, albeit reduced from a high of $34 billion to a current ...

Five years on, and Teva is still facing significant challenges, despite Schultz' best efforts. It is still saddled with a high level of debt that accompanied its takeover of Actavis, albeit ...